Novartis India recently announced an exclusive sales and distribution agreement with Dr Reddy’s Laboratories for a few of its established medicines which include the Voveran range, the Calcium range and Methergine, Novartis notified via a statement.
This arrangement aims to further broaden access to these medicines beyond the current geographies to benefit many more patients, more efficiently, by significantly extending the reach of healthcare professionals through an expanded field force, the statement added.
This brings together the manufacturing and development synergies of Novartis with the sales and distribution strengths of Dr Reddy’s, the statement further said.
Sanjay Murdeshwar, Country President and Managing Director, Novartis India, said, in the statement, “Today, on one hand, keeping the patient interest at the centre, we have entered this strategic business arrangement with Dr Reddy’s Laboratories to extend access to our established medicines to benefit more patients in India efficiently. On the other hand, we understand the implication on the roles of our colleagues in Novartis India, and are doing our best to support them.”
Both organisations will remain committed to patients, and will continue to focus on providing an uninterrupted supply of medicines, concluded the statement.